• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

NHSX GDE Blueprint Highlights Oxford VR’s Virtual Reality Therapy

Share:

April 28, 2020

Oxford VR’s automated virtual reality therapy has been featured in the latest NHSX Global Digital Exemplar (GDE) blueprint details.

Its programme has been integrated into NHS Improving Access to Psychological Therapies (IAPT) services since April last year.

The firm, which is a spinout from Oxford University’s department of psychiatry, played an instrumental role in creating the NHSX GDE blueprint ‘Virtual reality as a psychological tool’ which will help other NHS trusts to integrate and deliver VR therapy as part of building out their digital capabilities, to improve mental healthcare services for patients.

Included in the blueprint are details of the rollout process and key artefacts such as a standard operating procedure, a digital strategy and a data sharing template.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The blueprint is available on the Future NHSX Collaboration Platform.

WHY IT MATTERS

The COVID-19 pandemic has amplified the urgency of building capacity in mental healthcare to ensure trusts and providers can adequately meet acute demands for treatment and the longer-term mental health issues arising from this crisis.

Oxford VR automated therapy builds on two decades of research by Daniel Freeman, professor of clinical psychology and National Institute for Health Research (NIHR) research professor at Oxford University, investigating virtual reality’s potential to create a powerful new psychological treatment.

THE LARGER CONTEXT

Oxford VR’s mental health treatment uses immersive technology and evidence-based science to improve patient outcomes and increase capacity.

As well as collaborating with the NHS, it works with private healthcare providers in the UK such as Oasis Talk and charitable organisations including St Andrew’s Hospital trust.

The firm recently announced a £10 million ($12.9m) in a Series A funding round led by Optum Ventures, with support from Luminous Ventures – a record for virtual reality therapy investment in Europe.

It also recently launched a programme to help people with social anxiety by immersing them in virtual social situations, such as a grocery store or a bus ride.

Other players in the VR space include London-based FundamentalVR, which recently announced the expansion of its educational platform Fundamental Surgery to help train surgeons. Also British startup Touch Surgery reportedly borrowed $70 million earlier this year to fund its training augmented reality technology for doctors

ON THE RECORD

Barnaby Perks, founding CEO of Oxford VR said: “We are immensely proud that Oxford VR’s automated therapy is exemplified in the latest NHSX DGE Blueprint publication. In these unprecedented times for mental healthcare, digital transformation will be central to building capacity.

“This is an important Blueprint that NHS Trusts can turn to, for an evidence-based and highly scalable intervention, that is making a real-world impact and is based on years of rigorous research. ”

Source: MobiHealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • The Commons Project’s Free Personal Health Record for Android Now Supported By 230 Health SystemsThe Commons Project’s Free Personal Health Record for Android Now Supported By 230 Health Systems
  • Q-Centrix & Realyze Intelligence Partner to Advance the Clinical Data AutomationQ-Centrix & Realyze Intelligence Partner to Advance the Clinical Data Automation
  • VillageMD to Acquire Primary Care Medical Associates in ChicagoVillageMD to Acquire Primary Care Medical Associates in Chicago
  • EQT and CPPIB to acquire a Majority Equity Stake in Waystar in Transaction Valued at $2.7 BillionEQT and CPPIB to acquire a Majority Equity Stake in Waystar in Transaction Valued at $2.7 Billion
  • Current Health and Zoom Partner to Enable Equitable Care in the HomeCurrent Health and Zoom Partner to Enable Equitable Care in the Home
  • Included Health, Solv Partner to Connect Virtual & In-Person CareIncluded Health, Solv Partner to Connect Virtual & In-Person Care
  • Active Pharmaceutical Ingredient Market to Hit USD 261.28 Billion and Exhibit 6.1% CAGR by 2026Active Pharmaceutical Ingredient Market to Hit USD 261.28 Billion and Exhibit 6.1% CAGR by 2026
  • CDC Project Combines mHealth, Cash in Opioid Abuse TreatmentCDC Project Combines mHealth, Cash in Opioid Abuse Treatment

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications